Abstracts tagged "Inflammation"

Abstract Number: 1793 • ACR Convergence 2023
Goblet Cell Specific Anti-Apoptotic Role of Interleukin-24 in Spondyloarthritis-Associated Ileitis
Amy Cameron¹, Rabina Giri², Jakob Begun², Timothy Wells¹, Ranjeny Thomas³ and Anne-Sophie Bergot¹, ¹Frazer Institute, The University of Queensland, Woolloongabba, Australia, ²Mater Research Institute-UQ, Woolloongabba, Australia, ³Frazer Institute, The University of Queensland, Brisbane, Australia
Background/Purpose: The loss of intestinal barrier integrity is a key contributor to gut inflammation, however the mechanism behind this dysregulation is not well understood. The…
Abstract Number: 2358 • ACR Convergence 2023
Neutrophil Extracellular Traps Induce Endothelial-to-Mesenchymal Transition and Associate with Vascular Complications in Scleroderma
Ramadan Ali¹, Wenying Liang¹, Claire Shiple¹, Rosemary Gedert², Suiyuan Huang¹, Cyrus Sarosh¹, Eliza Pei-Suen Tsou¹, Dinesh Khanna¹ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Onsted, MI
Background/Purpose: Systemic sclerosis (SSc, also known as scleroderma) is a disease characterized by fibrosis, autoimmunity, and vasculopathy. Many devastating complications such as digital ulcerations, scleroderma…
Abstract Number: 017 • 2023 Pediatric Rheumatology Symposium
Potential Uveitic Biomarkers in Tears of Children with Juvenile Idiopathic Arthritis: A Pilot Study
Tiffany Nguyen¹, Ilaria Maccora¹, Mekibib Altaye¹, Wendy Haffey², Theresa Hennard¹, Alyssa Sproles¹, Sherry Thornton¹, Virginia Miraldi Utz¹, Ken Greis² and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²University of Cincinnati, Cincinnati, OH
Background/Purpose: Children diagnosed with oligoarticular juvenile idiopathic arthritis (JIA), the most commonly diagnosed subset of chronic arthritis, are at increased risk of developing uveitis. Known…
Abstract Number: 035 • 2023 Pediatric Rheumatology Symposium
SARS-CoV-2 Vaccination of Children with a History of Multisystem Inflammatory Syndrome
Mariana Sanchez Villa¹, Matthew Wisniewski¹, Jessica Nguyen¹, Eyal Muscal¹, Marietta Deguzman², Sara Kristen Sexson Tejtel¹, Sridevi Devaraj¹, Flor Munoz-Rivas¹, Leila Sahni¹ and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Most children who contract SARS-CoV-2 are asymptomatic or mildly symptomatic, but a subset subsequently develop the hyperinflammatory condition called multisystem inflammatory syndrome in children…
Abstract Number: 069 • 2023 Pediatric Rheumatology Symposium
Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios of Patients with Juvenile Systemic Lupus Erythematosus
Rogerio do Prado¹, Fabiola I Suano-Souza¹, Wellington D. R. Rodrigues², Lucila Pereira¹, Maria Teresa Terreri³ and Roseli O. S. Sarni⁴, ¹FMABC, São Paulo, Brazil, ²Unicid, São Paulo, Brazil, ³UNIFESP, São Paulo, Brazil, ⁴Centro Universitário Faculdade de Medicina do ABC (FMABC), Brazil
Background/Purpose: The Neutrophil-Lymphocyte ratio (NLR) and Platelet-Lymphocyte ratio (PLR) are markers of systemic inflammation easily available from the blood count. Previous studies have revealed that…
Abstract Number: 0019 • ACR Convergence 2022
Bacterial Peptidoglycan in Synovial Tissue at Time of Total Knee Arthroplasty Is Associated with Inflammatory Synovitis and Younger Patient Age
Meaghan Holub¹, Amanda Wahhab², Joseph Rouse², Brandon Jutras³, Klemen Strle⁴, Adam Edelstein⁵ and Robert Lochhead⁶, ¹Central Michigan University College of Medicine, Mount Pleasant, MI, ²Medical College of Wisconsin, Milwaukee, WI, ³Virginia Tech, Blacksburg, VA, ⁴Wadsworth Center, Albany, NY, ⁵Northwestern Medicine, Chicago, IL, ⁶Medical College of Wisconsin, Germantown, WI
Background/Purpose: Peptidoglycan (PG) is a bacterial cell wall component that is known to induce innate immune responses. PG has been identified as a driver of…
Abstract Number: 0419 • ACR Convergence 2022
Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Objective Signs of Inflammation at Baseline
Walter P Maksymowych¹, Xenofon Baraliakos², Atul Deodhar³, Denis Poddubnyy⁴, Fabiana Ganz⁵, Tianming Gao⁶, Jayne Stigler⁶, Anna K Shmagel⁶, Peter Wung⁶ and Filip Van den bosch⁷, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ³Oregon Health & Science University, Portland, OR, USA, Portland, OR, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵AbbVie, Inc., Luzern, Switzerland, ⁶AbbVie, Inc., North Chicago, IL, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium
Background/Purpose: The Phase 3 SELECT-AXIS 2 trial (NCT04169373) assessed the efficacy and safety of upadacitinib (UPA) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Here, we…
Abstract Number: 0609 • ACR Convergence 2022
Macrophage Response to MAA Modified Fibrinogen in the Presence of Peptidyl Arginine Deiminase Inhibitor
nozima Aripova¹, Michael Duryee¹, carlos hunter¹, Geoffrey Thiele¹ and Ted Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The formation of citrullinated (CIT) proteins is catalyzed by a calcium-dependent peptidyl arginine deiminase (PAD). In rheumatoid arthritis (RA), synovial macrophages are main contributors…
Abstract Number: 0992 • ACR Convergence 2022
Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
Amit Saxena¹, Samir Parikh², Richard Furie³, Richard Leff⁴, Steven Hua⁴, Li Long⁵ and Noreen Henig⁴, ¹NYU School of Medicine, New York, NY, ²The Ohio State University, Columbus, OH, ³Northwell Health, Great Neck, NY, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Kezar Life Sciences, Inc., South San Francisco, CA
Background/Purpose: Zetomipzomib is a first-in-class selective inhibitor of the immunoproteasome that is active in multiple autoimmune disease models, including murine models of SLE and LN.…
Abstract Number: 1503 • ACR Convergence 2022
Is Inflammation-driven Bone Loss Associated with Two-year Bone Formation at the Same Vertebra in Axial Spondyloarthritis? – a Multilevel MRI and Low Dose CT Analysis from the Sensitive Imaging of Axial Spondyloarthritis (SIAS) Cohort
Mary Lucy Marques¹, Nuno Pereira da Silva², Désirée van der Heijde³, Rosalinde Stal⁴, Xenofon Baraliakos⁵, Juergen Braun⁶, Monique Reijnierse⁴, Caroline Bastiaenen⁷, Sofia Ramiro⁴ and floris van Gaalen⁴, ¹Leiden University Medical Center, Coimbra, Portugal, ²Radiology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Department of Epidemiology, Maastricht University, Maastricht, Netherlands
Background/Purpose: In radiographic axial spondyloarthritis (r-axSpA), inflammation-driven trabecular bone loss is hypothesised to trigger bone repair at an anatomically distinct site of the same vertebra…
Abstract Number: 1777 • ACR Convergence 2022
A Symptom Checker App Is Better at Classifying Inflammatory Disease Than Physicians Who Are Presented Identical Information
markus Gräf¹, Johannes Knitza², Jan Leipe³, Martin Krusche⁴, Martin Welcker⁵, Sebastian Kuhn⁶, Johanna Mucke⁷, Axel Hueber⁸, Johannes Hornig⁹, Philipp Klemm¹⁰, stefan Kleinert¹¹, Peer Aries¹², Nicolas Vuillerme¹³, Arnd Kleyer², Georg Schett¹⁴ and Johanna Callhoff¹⁵, ¹Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Division of Rheumatology, Department of Medicine V, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany, ⁴University Hospital Hamburg-Eppendorf, Hamburg, Germany, ⁵GBR, Planegg, Germany, ⁶Department of Digital Medicine, Medical Faculty OWL, Bielefeld University, Bielefeld, Germany, ⁷Policlinic and Hiller Research Center, Heinrich-Heine-University Duesseldorf, Neuss, Germany, ⁸Paracelsus University Nürnberg, Erlangen, Germany, ⁹Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, ¹⁰Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, ¹¹Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ¹²Rheumatologie im Struenseehaus, Hamburg, Germany, ¹³Université Grenoble Alpes, AGEIS, Grenoble, France, ¹⁴Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁵German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: The purpose of this study was to compare the ability of an artificial intelligence-based symptom checker app (Ada) and physicians to determine the presence/absence…
Abstract Number: 2008 • ACR Convergence 2022
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs
Alan Kivitz¹, Liangwei Wang², Ilias Alevizos², Michele Gunsior², Judith Falloon² and Gabor Illei³, ¹Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ²Horizon Therapeutics, Gaithersburg, MD, ³Horizon Therapeutics, Rockville, MD
Background/Purpose: Dazodalibep (DAZ), a non-antibody biologic antagonist of CD40L, led to higher/durable response rates vs. placebo (PBO) in a double-blind, Phase 1b trial of patients…
Abstract Number: 0026 • ACR Convergence 2022
Silencing of WISP-2 Induces Inflammatory Mediators and Catabolic Factors in Cartilage
Clara Ruiz-Fernández¹, María González-Rodríguez², Vera Francisco³, Djedjiga Ait Eldjoudi², Alfonso Cordero-Barreal², Yousof Farrag², Jesús Pino⁴, Miguel Ángel González-Gay⁵, Antonio Mera⁶, Francisca Lago² and Oreste Gualillo⁷, ¹Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Galicia, Spain, ²Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain, ³Institute of Health Research-INCLIVA, València, Spain, ⁴Santiago Clinic Hospital CHUS-Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain, ⁵Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁶Santiago University Clinical Hospital CHUS, Santiago de Compostela, Spain, ⁷Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain
Background/Purpose: Wnt-1 inducible signaling pathway protein 2 (WISP-2/CCN5) is an adipokine that has been described as an important mediator of canonical Wnt activation in adipogenic…
Abstract Number: 0482 • ACR Convergence 2022
Role of miR-146a and miR-146b in Giant Cell Arteritis
Martina Bonacini¹, Alessandro Rossi¹, Ilaria Ferrigno², Francesco Muratore¹, Luigi Boiardi¹, Alberto Cavazza¹, Luca Cimino², Angelo Ghidini¹, Giuseppe Malchiodi¹, Marc Corbera-Bellalta³, Maria C Cid³, Alessandro Zerbini¹, Carlo Salvarani⁴ and Stefania Croci¹, ¹Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, University of Modena and Reggio Emilia, Reggio Emilia, Italy, ³Hospital Clinic, University of Barcelona, Barcelona, Spain, ⁴Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory disease of large and medium-sized arteries. MiRNAs (miR) are small, non-coding RNAs that inhibit gene expression at…
Abstract Number: 0614 • ACR Convergence 2022
Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
nozima Aripova¹, Michael Duryee¹, carlos hunter¹, Eric Daubach¹, Evan Ryan¹, Geoffrey Thiele¹ and Ted Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cellular interactions between synovial macrophages and human fibroblast-like synoviocytes (HFLS) contribute to articular inflammation and fibrosis in rheumatoid arthritis (RA), leading to subsequent joint…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].